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T3 (3,5,3 -triiodothyronine) has drawn relatively little attention in relation to cardiovascular (CVS) diseases. The present study
was designed to evaluate the cardioprotective action of T3 in isoproterenol-(ISO-) induced cardiac toxicity. Female Wistar rats
were exposed with ISO (100mg/kg, body weight, subcutaneously) for 2 days at the interval of 24h followed by T3 (3μg/kg,
body weight, orally) treatment for 3 days. Positive control rats received only ISO (100mg/kg, body weight, subcutaneously) for
2 days at the interval of 24hrs. Control group animals received normal saline as a vehicle. As expected, ISO-induced signiﬁcant
changes were observed in low-density lipoprotein, total cholesterol, ALT, CK-MB to TCK ratio, and prolongation of QT interval in
electrocardiogram, which is toward normalization after T3 treatment. Lower heart weight, upregulation of cardiac myosin heavy
chain alpha (MHC-α), and reduced inﬂammatory cell inﬁltration, myonecrosis, vacuolar changes, and a trend toward normal
cardiac muscle ﬁber architecture in microscopic examination of cardiac tissue further support the cardioprotective eﬀect of T3.
1.Introduction
In the past decades, a diﬀerent class of drugs has been
used for the control of myocardial ischemia and associated
pathologies, but thyroid hormone has attracted relatively
little attention in relation to CVS diseases. Heart ischemia
is one of the main causes related to sudden death in the
world. It is believed that exogenous supply of T3 causes
increase in heart rate, in myocardial infarction leading to
higher mortality rate and low T3 levels have cardioprotective
action in heart diseases. Recent data has shown that low
levels of triiodothyronine (T3)i nc a s eo fh e a r tf a i l u r ea r e
often associated with increased mortality and morbidity [1–
3]. The interaction between thyroid hormone and heart
indicates that T3 levels as well as clinical severity may be
correlated with myocardial contractility in the patient with
stress cardiomyopathy [4]. It is well known that ISO-induced
cardiotoxicity in rat models is a widely used for evaluation
of cardioprotective eﬀect of various drugs. ISO causes severe
stress in the myocardial tissue of animals resulting in myo-
cardial infarction in animals due to the action on the
sarcolemmal membrane, stimulation of adenylate cyclase,
activation of Na+ and Ca2+ channels, and exaggerated Ca2+
inﬂow and energy consumption leading to cellular death.
Additionally, free radicals produced by ISO could initiate
peroxidation of membrane bound polyunsaturated fatty
acids, leading to both functional and structural myocardial
injuries [5]. Therefore, a cardioprotective eﬀect of T3 needs
to be demonstrated clearly in animal models.
With these objectives in mind, developing new therapeu-
tic strategies to treatspeciﬁc cardiac diseases through thyroid
hormones can be an added advantage in area of medical
research.
2.MaterialsandMethods
2.1. Experimental Animals. Healthy young nulliparous fe-
male Wistar rats 5–7 weeks (120 ± 15g), obtained from2 International Journal of Endocrinology
Animal Research Facility of Zydus Research Centre, Ahmed-
abad, were housed in IVC (Individually Ventilated Cage)
under standard laboratory conditions: temperature (25 ±
3◦C), relative humidity (30 to 70%), and photoperiod (light
and dark cycle of 12h each) with food and water provided ad
libitum. Protocol for this study was approved by Institutional
Animal Ethics Committee (IAEC).
2.2. Experimental Design. Female rats were randomized into
four groups comprising of ﬁve animals in each group.
Group I. Control rats received normal saline subcutaneously
forﬁrst2daysanddistilledwaterremaining3daysviagastric
intubation.
Group II. Rats received ISO in normal saline subcutaneously
(100mg/kgb·wt/day), at an interval of 24h for two days.
Group III. Rats received T3 (3μg/kgb·wt/day) orally by
gavage for 3 consecutive days after 2 days ISO treatment.
Group IV. Rats treated with T3 alone (3μg/kgb·wt/day) via
gastric intubation for 5 consecutive days.
Extra set of animals comprising ﬁve animals in each
groups were used for electrocardiogram.
2.3. Dose Selection. A pilot study was conducted to establish
the optimum dose of the T3 and its duration of treatment
which exhibits maximum cardioprotective eﬀect. Rats were
treated with T3 ( 1 ,3 ,5 ,8a n d1 5μg/kg/day, p.o.) of duration
3,7,and14daysafter2daystreatmentwithisoproterenol.At
the end of treatment, serum markers such as Alanine amino-
transferase (U/L), Alkaline phosphatase (U/L), Aspartate
aminotransferase (U/L), Creatine Kinase (U/L), and CKMB
(IU/L) were evaluated. T3 (3μg/kg/day, p.o.) of duration
3d a y sw a sf o u n dt ob em o s te ﬀective in reverting the
biochemicalalterationinducedbyIsoproterenol.Inaddition,
exploratory study of Isoproterenol was also carried out (60,
80, 100, 150, and 200mg/kg/day, s.c.), dose of 100mg/kg was
selected based on high mortality at 150 and 200mg/kg, and
clear cut serum cardiac marker changes at 100mg/kg.
2.4. Test Chemical. 3,5,3 -triiodo-L-thyronine (T3)[ S i g m a -
Aldrich, USA], Isoprenaline hydrochloride, [Sigma-Aldrich
Chemical Pvt. Ltd., USA], Polyoxyethylene sorbitan mo-
nooleate (Tween 80) [Merck specialities private limited,
Bombay, India], Dimethyl sulphoxide (DMSO) [Qualigens
ﬁne chemicals GlaxoSmithkLine Pharma Limited, Bombay,
India], TRIzol reagent [Invitrogen, Life Technologies, Cars-
bad, CA, USA].
2.5. Observations
2.5.1. Electrocardiogram. Electrocardiogram was measured
at the end of treatment period (Day 6). The electrocardio-
graphic patterns were recorded by three lead-sixteen channel
polygraph (Biopac Systems Inc., USA). Parameters evaluated
were PQ, QT, RR, and QRS interval. Female Wistar rats were
anaesthetized with ketamine and xylazine at a dose of 70 and
7mg/kgb·wt, respectively, by intraperitoneal route for ECG
measurement.
2.6. Clinical Pathology. Blood samples were collected from
retro-orbital plexus for serum biochemistry and hormonal
proﬁle at the end of treatment to correlate results of ECG,
histopathology, and gene expressions studies.
2.6.1. Serum Biochemistry. Biochemical analysis was done
using Daytona autoanalyser (Randox Laboratories, UK).
Details of analytes evaluated and the methods used are as
follows: total cholesterol (mg/dL) (TC-cholesterol oxidase),
low-density lipoprotein (mg/dL) (LDL-Direct clearance),
alanine aminotransferase (U/L) (ALT-UV without p5p),
alkaline phosphatase (ALP-PNP AMP buﬀer), aspartate
aminotransferase (U/L) (AST-UV), calcium (mg/dL) (Arse-
nazo), creatine kinase (U/L) (CK-UV: NAC activated), total
T3 (TT3),andtotalthyroxine(TT4)wereestimatedbyELISA
method (CL, Biotech), CKMB (IU/L) (ELISA method CL,
Biotech).
2.7. Histopathology. At terminal necropsy (day 6), animals
were humanely euthanised by carbon dioxide asphyxiation.
Animals were subjected to complete gross examination.
Weight of the heart was estimated and ﬁxed in 10%
formal saline. Paraﬃn sections were prepared and stained
with hematoxylin-eosin for histopathological examination.
Massion’s Trichrome special stain was done for ﬁbroblast.
2.8. Gene Expression. Tissue samples from heart were dis-
sected and snap-frozen in liquid nitrogen immediately at
terminal necropsy and stored at −70 ± 2◦C for further
analysis. Equal amount of frozen heart tissue and TRIZOL
reagent (1mL/100mg of tissue) was homogenized and
total RNA (Ribonucleic acid) was isolated. Quantitation of
total RNA was performed using Biophotometer (Eppen-
dorf, Germany), and the quality of RNA was ascertained
by agarose gel electrophoresis. For gene expression of
MHC-alpha, Myh6F-(CACCCTGGAGGACCAGATTA) and
Myh6R-(TGGATCCTGATGAACTTCCC) speciﬁc RT-PCR
(Real Time-Polymerase Chain Reaction) primers were used.
First-strand cDNA (Complementary deoxyribonucleic acid)
synthesis was achieved with 2μg of total RNA in a ﬁnal
volume of 20μL. About 2μL from this reaction cocktail
was used directly to conduct PCR ampliﬁcation in presence
of SYBR-Green following real-time RT-PCR using ABI-
7300 system (Applied Biosystem, Singapore). SYBR Green-
based real time RT-PCR was used to estimate the levels
of transcripts (MHC-alpha) expressed in heart samples
collected from experimental groups.
2.9. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism Version 4.00. Data was analyzed
for statistical signiﬁcance by dose-wise by using GraphPad
Prism Version 4.00. Numerical results were processed to get
group mean and standard deviation. ANOVA (Analysis of
Variance) was used for the comparison of diﬀerent doseInternational Journal of Endocrinology 3
Table 1: Eﬀect of T3 on electrocardiogram parameters in ISO-induced cardiac changes.
Group/Dose (I)/Vehicle control (II)/ISO (100mg/kg) (III)/ISO + T3 (3μg/kg) (IV)/T3 (3μg/kg)
QT interval (ms) 93.33 ± 5.77 146.67 ± 15.28∗∗ 100.00 ± 14.52## 86.33 ± 3.51##
QRS interval (ms) 40.00 ± 4.15 30.33 ± 3.55∗ 43.33 ± 5.77 39.00 ± 3.61
Values are presented as Mean ± SD, n = 5, ∗P<0.05 versus control, ∗∗P<0.01 versus control, #P<0.05 versus ISO (100mg/kg), ##P<0.01 versus ISO
(100mg/kg), SD: Standard Deviation, ECG parameters are expressed in milisecond.
Table 2: Summary of hormonal proﬁle.
Parameter (I)/Vehicle control (II)/ISO (100mg/kg) (III)/ISO + T3 (3μg/kg) (IV)/T3 (3μg/kg)
Total T3 (ng/mL) 1.17 ± 0.13 1.08 ± 0.07 1.10 ± 0.02 1.06 ± 0.08
Total T4 (μg/mL) 5.35 ± 1.23 2.80 ± 0.53∗ 2.81 ± 0.40∗∗ 1.95 ± 0.55∗∗
Values are presented as Mean ± SD, n = 5, ∗P<0.05 versus control, ∗∗P<0.01 versus control, #P<0.05 versus ISO (100mg/kg), ##P<0.01 versus ISO
(100mg/kg), SD: Standard Deviation.
groups with the control and ISO-treated group. Post hoc test




3.1. Electrocardiogram. Morphological evaluation of electro-
cardiogram revealed marked changes in ST segment and T
wave. ISO-(100mg/kg) treated groups showed marked T-
wave depression and complete T-wave inversion. Signiﬁcant
prolonged QT interval and decrease QRS interval was found
in ISO-(100mg/kg) treated group, whereas the combination
group (ISO + T3) showed normalization trend of T-waves,
QT interval, and QRS interval. Heart rate was increased in
ISO injected rats compared to control rats and was found
nonsigniﬁcant. T3-treated group alone was comparable with
control group (Figure 5)( Table 1).
3.2. Lipid Proﬁle. LDL level was signiﬁcantly increased by
197.9% (∗∗P<0.01) in ISO-treated rats in comparison
with control rats. Treatment with T3 in ISO-injected rats
(T3 + ISO) showed signiﬁcant low level of LDL by 67.4%
(##P<0.01), which was observed in comparison with ISO
treated rats (Figure 1). A signiﬁcant (∗P<0.05) elevation in
total cholesterol was observed in ISO administered animals
in comparison to control group which was reduced after (T3
+ ISO) treatment.
3.3.CardiacInjuryMarker. Approximately,2-foldsigniﬁcant
elevation in ALT (∗∗P<0.01) was noticed in ISO-treated
rats in comparison with control rats. Treatment with T3 in
ISO-injected rats shown a signiﬁcant decline in ALT (##P<
0.01), in comparison with ISO-treated rats (Figure 2). T3
alone treated rats showed a signiﬁcant decrease in ALT level
in comparison with ISO-treated rats. CKMB: CK ratio was
foundtobesigniﬁcantlyhigherby79.6%(∗P<0.05)inISO-
treated animals, which was signiﬁcantly reduced after T3 +


















































































Figure 1: Eﬀect of T3 on low-density lipoprotein, values are
presented as Mean ± SD, n = 5, ∗∗: signiﬁcant from control group
at 1% level (P<0.01), ##: signiﬁcant from ISO control at 1% level
(P<0.01), SD: Standard Deviation.
3.4. Hormonal Proﬁle. Signiﬁcant decrease in total thyroxine
was noticed in all groups in comparison with control
groups. However, no changes were observed in total T3 levels
(Table 2).
3.5. Heart to Body Weight Ratio. Relative heart weight was
found signiﬁcantly increased by 42.5% (∗∗P<0.01) in ISO-
treated rat in comparison with control rats. After treatment
with T3 in ISO-injected rats, heart weight was signiﬁcantly
reduced by 19.21% (#P<0.05), in comparison with ISO-
treated rats (Figure 4).
3.6. MHC-α Gene Expression. Signiﬁcant downregulation
of MHC-α expression was seen by 70.3% (∗P<0.05) in
ISO-treated rats in comparison with control rats. T3 in
combination with ISO and T3 treatment alone revealed
marked upregulation of MHC-α in comparison with only
ISO-treated rats (Figure 6). This upregulation of MHC-α
















































































Figure 2: Eﬀect of T3 on ALT, values are presented as Mean ± SD,
n = 5, ∗∗: signiﬁcant from control group at 1% level (P<0.01), ##:























































































Figure 3: Eﬀect of T3 on CKMB: CK Ratio, values are presented as
Mean ± SD, n = 5, ∗: signiﬁcant from control group at 0.05% level
(P<0.05), #: signiﬁcant from ISO control group at 0.05% level
(P<0.05), ##: signiﬁcant from ISO control at 1% level (P<0.01),
SD: Standard Deviation.
3.7. Histopathological Findings in Heart. Microscopic exam-
ination of heart tissue revealed moderate to severe car-
diomyopathyinISO-treatedgroup(5/5).Therewasextensive
myocyte membrane damage, myo-necrosis, proliferation of
ﬁbroblast, and inﬁlration of mononuclear cells in ISO-
treated group. In ISO + T3, group revealed minimal damage
to the myocardium with much reduced myonecrosis, edema,
and lymphocytic inﬁlration in comparison with ISO group.
No changes were noticed in control and T3 alone treated rats
(Figure 7). Conﬁrmation of proliferation of ﬁbroblast was
done with Massion Trichome.
4. Discussion
Lipid proﬁle plays an important role in the pathogenesis of
cardiovascular diseases, not only by way of hyperlipidemia
and development of atherosclerosis, but also by modiﬁcation
of composition, structure, and stability of the cellular mem-
branes. ISO markedly raises the low-density lipoprotein and
total cholesterol levels [6]. A strong positive correlation has




































































































± SD, n = 5, ∗∗: signiﬁcant from control group at 1% level (P<
0.05), ##: signiﬁcant from ISO control group at 1% level (P<0.05),
SD: Standard Deviation.
heartdiseaseandserumLDLlevel[7].PosttreatmentwithT3
successfully restored the elevated LDL-cholesterol and total
cholesterol levels in the treatment group. These eﬀects of
T3 may be due to rapid increase in hepatic LDL receptor
mRNA to promote the LDL clearance process [8, 9]. These
alterations by T3 indicate the well-known physiological
actions of T3 on lipid metabolism.
CK-MB isoenzyme activity is useful for both early diag-
nosis of myocardial infarction and other types of myocardial
injury. CK-MB, TCK, AST, ALT, and ALP, which serve as
the diagnostic markers, leak out from the damaged tissue to
blood stream when cell membrane becomes more permeable
or when rupture [10]. Sometimes serum CK-MB may raise
as a result of noncardiac muscle damage, so the ratio of CK-
MB to TCK is preferred over CK-MB alone. In the present
study, ISO injected Wistar female rats showed signiﬁcant
elevation in the levels of ALT and CK-MB to TCK ratio,
which were corroboration with the previous reports and
ﬁndings of ISO such as necrotic damage of the myocardium
and leakiness of the plasma membrane. T3 posttreatment
resulted in the lowered activity of the marker enzymes
in serum. Our observations demonstrated that T3 could
maintain membrane integrity, thereby restricting the leakage
of these enzymes [11].
ISO administration in rats showed treatment-related
adverse eﬀects in electrocardiogram. There was a signiﬁcant
prolongation in QT interval and decrease QRS interval.
These changes may be due to consecutive loss of cell
membrane in injured myocardium [12]. Changes in T-waves
morphology in ISO treated animals indicates myocardial
edema as a result of loss of cell membrane function [13].
These abnormal changes in ECG were not noticed in animals
treated with T3 after ISO administration suggestive of the
protective cell membrane role of T3.
Exogenous administration of T3 has negative feedback
suppressive eﬀects on endogenous thyroxine levels than
control rats. It is interesting to note that ISO-treated rats
showed signiﬁcant reduction in total thyroxine level in
comparison with control group. This indicates that low
thyroxine level may be responsible for cardiac adverse eﬀects,International Journal of Endocrinology 5
(a) Control
(b) ISO (100mg/kg)




and clinical evidence. Low thyroid hormone states in heart
failure are often associated with increased mortality and
morbidity [2].
T h er e l a t i v ee x p r e s s i o no fα-a n dβ-MHC isoforms is
altered in diseased state such as cardiac hypertrophy or
failure where a shift from the normally predominant α-
MHC toward β-MHC is observed [14, 15]. As a result,
upregulation of β-MHC transcription is considered as an
early and sensitive marker of cardiac hypertrophy [16]. β-
MHC is characterized by lower ﬁlament sliding velocity
but has a higher economy of energy consumption than α-
MHC [17, 18]. This suggests that a shift from α to β-





























































































Figure 6: Eﬀect of T3 on relative expression of MHC-α. Values are presented as Mean ± SD, n = 5, ∗∗: signiﬁcant from control group at 1%
level (P<0.01), SD: Standard Deviation.
(a) Normal Heart H and E 20x (b) ISO(100mg/kg)treatedrat:moderateto
severe cardiomyopathy indicating myocyte
degeneration, ﬁbrous tissue proliferation
and necrotic foci. H and E 20x
(c) ISO + T3 treated rats: myocardial tissue
showsreducedinﬂammatorycellinﬁltration,
no evidence of myonecrosis tends to revert
normalcy. H and E 20x
(d) No changes noticed in myocardial tissue
treated alone with T3 at 3μg/kg
(e) ISO (100mg/kg): ﬁbrous tissue pro-
liferation in myocardial tissue Massion’s
Trichrome 20x
Figure 7: Histopathology of cardiac tissue.
energy.Studiesontransgenicmiceexpressingpredominantly
β-MHC showed reduced mechanical function suggesting
increased β-MHC expression which may have a detrimental
eﬀect on heart failure [19]. Increased β-MHC indicates the
underlying adverse cardiac remodelling.
T3 treatment eﬀectively prevented the relative shift in
isoforms, from α-MHC to β-MHC, and may contribute to
its beneﬁcial eﬀect in cardiac hypertrophy. It might be due
to inhibition of the remodelling process by T3. Cardiac tissue
of ISO-treated rats showed signiﬁcantly downregulation ofInternational Journal of Endocrinology 7
MHC-α gene which indirectly indicates the upregulation
MHC-β gene and may be responsible for deleterious eﬀect in
heart.T3 increasedMHC-αsynthesisbyincreasingtheDNA-
dependent RNA synthesis and decreased MHC-β synthesis
by inhibiting the DNA-dependent RNA synthetase enzyme.
Following ISO administration, signiﬁcant higher weight
of heart in comparison with control was noticed, which
was signiﬁcantly low in T3 + ISO-treated rats. Higher heart
weight might be attributed to increased water content,
edematous intramuscular space [20], and increased protein
content. Posttreatment of T3 does not alter heart weight to
longer extent indicative of its protective role on myocardium
against mucopolysaccharides and cellular inﬁltration and
thus preventing intramuscular edema. This may be further
correlated with inhibition of relative shift from α-MHC to β-
MHC by T3 and indicates its beneﬁcial eﬀect in preventing
cardiac hypertrophy [21]. It is interesting to note that no
change in heart weight was observed in T3-treated alone
group rats at 3μg/kg.
Histopathological examination of cardiac tissue revealed
moderate to severe cardiomyopathy which includes myocyte
degeneration, inﬂammatory cell inﬁltration, ﬁbrous tissue
proliferation, and necrotic foci in ISO-treated animals. T3 in
combinationofISOshowedminimalinﬂammatorycellinﬁl-
tration and trend toward normal cardiac muscle ﬁber archi-
tecture further conﬁrmed the cardio protective eﬀect of T3.
5. Conclusion
Administration of T3 hormone reveals the cardioprotective
role from Isoproterenol-induced myocardial infarction in
Wistar rats in this study. This was evident from the reversal
of serum enzymes, ECG, and MHC gene expression proﬁle
and a trend towards normalization of cardiac muscle ﬁber
architecture in histopathological evaluation.
Acknowledgment
Authors sincerely acknowledge each and every team member
of Toxicological Section of Zydus Research Centre for their
valuable support in completing this work.
References
[1] I.Lymvaios,I.Mourouzis,D.V.Cokkinos,M.A.Dimopoulos,
S. T. Toumanidis, and C. Pantos, “Thyroid hormone and
recovery of cardiac function in patients with acute myocar-
dial infarction: a strong association?” European Journal of
Endocrinology, vol. 165, no. 1, pp. 107–114, 2011.
[2] C.Pantos,A.Dritsas,I.Mourouziset al., “Thyroidhormoneis
a critical determinant of myocardial performance in patients
with heart failure: potential therapeutic implications,” Euro-
pean Journal of Endocrinology, vol. 157, no. 4, pp. 515–520,
2007.
[3] C.Pantos,I.Mourouzis,K.Markakisetal.,“Thyroidhormone
attenuates cardiac remodeling and improves hemodynamics
early after acute myocardial infarction in rats,” European
Journal of Cardio-thoracic Surgery, vol. 32, no. 2, pp. 333–339,
2007.
[ 4 ]S .J .L e e ,J .G .K a n g ,O .K .R y ue ta l . ,“ T h er e l a t i o n s h i po f
thyroid hormone status with myocardial function in stress
cardiomyopathy,” European Journal of Endocrinology, vol. 160,
no. 5, pp. 799–806, 2009.
[5] D. Grimm, D. Elsner, H. Schunkert et al., “Development of
heart failure following isoproterenol administration in the rat:
roleoftherenin-angiotensinsystem,”CardiovascularResearch,
vol. 37, no. 1, pp. 91–100, 1998.
[6] R. Anandan, S. Mathew, T. V. Sankar, and P. G. Viswanathan
Nair, “Protective eﬀect of n-3 polyunsaturated fatty acids
concentrate on isoproterenol-induced myocardial infarction
in rats,” Prostaglandins Leukotrienes and Essential Fatty Acids,
vol. 76, no. 3, pp. 153–158, 2007.
[7] S. Mediene-Benchekor, T. Brousseau, F. Richard et al., “Blood
lipid concentrations and risk of myocardial infarction,” The
Lancet, vol. 358, no. 9287, pp. 1064–1065, 2001.
[8] B. Staels, A. Van Tol, L. Chan, H. Will, G. Verhoeven, and J.
Auwerx, “Alterations in thyroid status modulate apolipopro-
tein, hepatic triglyceride lipase, and low density lipoprotein
receptor in rats,” Endocrinology,vol.127,no.3,pp.1144–1152,
1990.
[ 9 ]S .A .W i s e m a n ,J .T .P o w e l l ,S .E .H u m p h r i e s ,a n dM .P r e s s ,
“The magnitude of the hypercholesterolemia of hypothy-
roidism is associated with variation in the low density
lipoprotein receptor gene,” Journal of Clinical Endocrinology
and Metabolism, vol. 77, no. 1, pp. 108–112, 1993.
[10] I. Mohanty, D. S. Arya, A. Dinda, K. K. Talwar, S. Joshi, and S.
K. Gupta, “Mechanisms of cardioprotective eﬀect of Withania
somnifera in experimentally induced myocardial infarction,”
Basic and Clinical Pharmacology and Toxicology, vol. 94, no. 4,
pp. 184–190, 2004.
[11] Y. F. Chen, S. Kobayashi, J. Chen et al., “Short term triiodo-
l-thyronine treatment inhibits cardiac myocyte apoptosis in
border area after myocardial infarction in rats,” Journal of
Molecular and Cellular Cardiology, vol. 44, no. 1, pp. 180–187,
2008.
[12] W. F. Peacock, J. E. Hollander, R. W. Smalling, and M. J.
Bresler, “Reperfusion strategies in the emergency treatment
of ST-segment elevation myocardial infarction,” American
Journal of Emergency Medicine, vol. 25, no. 3, pp. 353–366,
2007.
[13] M. Rajadurai and P. S. M. Prince, “Preventive eﬀect of
naringin on cardiac markers, electrocardiographic patterns
and lysosomal hydrolases in normal and isoproterenol-
induced myocardial infarction in Wistar rats,” Toxicology, vol.
230, no. 2-3, pp. 178–188, 2007.
[14] K. Harada, T. Sugaya, K. Murakami, Y. Yazaki, and I. Komuro,
“Angiotensin II type 1A receptor knockout mice display
less left ventricular remodeling and improved survival after
myocardial infarction,” Circulation, vol. 100, no. 20, pp. 2093–
2099, 1999.
[15] B. Nadal-Ginard and V. Mahdavi, “Molecular basis of cardiac
performance. Plasticity of the myocardium generated through
protein isoformswitches,”JournalofClinicalInvestigation,vol.
84, no. 6, pp. 1693–1700, 1989.
[16] W. K. Jones, I. L. Grupp, T. Doetschman et al., “Ablation
of the murine α myosin heavy chain gene leads to dosage
eﬀects and functional deﬁcits in the heart,” Journal of Clinical
Investigation, vol. 98, no. 8, pp. 1906–1917, 1996.
[17] D. E. Harris, S. S. Work, R. K. Wright, N. R. Alpert, and D. M.
Warshaw, “Smooth, cardiac and skeletal muscle myosin force
and motion generation assessed by cross-bridge mechanical
interactions in vitro,” J o u r n a lo fM u s c l eR e s e a r c ha n dC e l l
Motility, vol. 15, no. 1, pp. 11–19, 1994.8 International Journal of Endocrinology
[18] S. Sugiura, N. Kobayakawa, H. Fujita et al., “Comparison of
unitary displacements and forces between 2 cardiac myosin
isoforms by the optical trap technique: molecular basis for
cardiac adaptation,” Circulation Research, vol. 82, no. 10, pp.
1029–1034, 1998.
[19] M. Krenz, A. Sanbe, F. Bouyer-Dalloz et al., “Analysis of
myosin heavy chain functionality in the heart,” Journal of
Biological Chemistry, vol. 278, no. 19, pp. 17466–17474, 2003.
[20] C. Nirmala and R. Puvanakrishnan, “Protective role of
curcuminagainstisoproterenolinducedmyocardialinfarction
in rats,” Molecular and Cellular Biochemistry, vol. 159, no. 2,
pp. 85–93, 1996.
[21] T. Asahi, M. Shimabukuro, Y. Oshiro, H. Yoshida, and N.
Takasu, “Cilazapril prevents cardiac hypertrophy and postis-
chemicmyocardialdysfunctioninhyperthyroidrats,”Thyroid,
vol. 11, no. 11, pp. 1009–1015, 2001.